Morningstar

Partner Therapeutics Announces FDA Approval of BIZENGRI® (Zenocutuzumab-zbco) for NRG1 Fusion-Positive Cholangiocarcinoma Following Receipt of FDA Commissioner's National ...

LEXINGTON, Mass., May 11, 2026 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx), a private, fully integrated biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has ...
Pharmabiz

Partner Therapeutics’ Bizengri gets US FDA approval for NRG1 fusion-positive cholangiocarcinoma following receipt of FDA commissioner’s National Priority Voucher

Partner Therapeutics, Inc. (PTx), a private, fully integrated biotechnology company, announced that the US Food and Drug Administration (FDA) has approved Bizengri (zenocutuzumab-zbco) for the ...
Morningstar

Partner Therapeutics Announces Receipt of FDA Commissioner's National Priority Voucher for BIZENGRI® (Zenocutuzumab-zbco) in NRG1 Fusion-Positive Cholangiocarcinoma

LEXINGTON, Mass., May 6, 2026 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx), a private, fully integrated biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has ...